Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Rises By 177.1%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 16,388 shares, an increase of 177.1% from the May 14th total of 5,914 shares. Based on an average trading volume of 8,366 shares, the days-to-cover ratio is currently 2.0 days. Approximately 0.8% of the company’s stock are sold short.

Xenetic Biosciences Stock Performance

NASDAQ XBIO traded up $0.22 on Friday, reaching $3.22. The stock had a trading volume of 14,546 shares, compared to its average volume of 20,483. Xenetic Biosciences has a 12-month low of $1.90 and a 12-month high of $13.93. The business’s 50-day moving average price is $3.12 and its 200 day moving average price is $2.66. The stock has a market cap of $7.37 million, a P/E ratio of -2.70 and a beta of 2.19.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The business had revenue of $0.81 million for the quarter.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC acquired a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences as of its most recent SEC filing. Institutional investors own 15.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Xenetic Biosciences has a consensus rating of “Sell”.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.